sialyl-Tn (STn)

May 9, 2018

Siamab’s ST1 Therapy Candidate Promising Against Chemoresistant Ovarian Cancer, Study Shows

News

Siamab Therapeutics‘ investigational antibody-drug conjugate ST1 has promising anti-tumor effects against chemotherapy-resistant ovarian cancer in cell and animal models, a study shows. The study, “Treatment of ovarian cancer by targeting the tumor stem cell-associated ... Read more

September 26, 2016September 26, 2016

Siamab Therapeutics’ Antibody Drug Conjugates Show Promising Results in Ovarian Cancer

News

On Sept. 12, at the American Association for Cancer Research (AACR)’s 11th Biennial Ovarian Cancer Research Symposium in Seattle, Siamab Therapeutics declared that its new ST1 antibody drug conjugates (ADCs) have ... Read more